- US-listed companies
- NeuBase Therapeutics, Inc.
- Income statement
NeuBase Therapeutics, Inc.NBSE
Market cap
$1.41M
P/E ratio
| 2011/09 | 2012/09 | 2013/09 | 2014/09 | 2015/09 | 2016/09 | 2017/09 | 2018/09 | 2019/09 | 2020/09 | 2021/09 | 2022/09 | |
| Research & development | 800,520 | 2 | 5 | 4 | 9 | 16 | 17 | 4 | 4 | 7 | 11 | 21 |
| Operating income | -1,243,401 | -3,286,408 | -4,620,916 | -9,122,924 | -17,805,280 | -24,596,053 | -23,780,073 | -13,903,955 | -26,336,407 | -17,069,306 | -26,565,447 | -33,318,339 |
| Operating expenses | 4 | 7 | 12 | 9 | - | - | - | - | 26 | 17 | 27 | 33 |
| Income before tax | -5,101,519 | -1,454,884 | -5,652,488 | -9,130,664 | -15,197,865 | -25,766,198 | -23,810,996 | - | - | - | - | - |
| Provision for income taxes | - | - | - | - | - | - | - | -13,236,900 | - | - | - | - |
| Net income | -5,101,519 | -1,454,884 | -5,652,488 | -9,130,664 | -15,197,865 | -25,766,198 | -23,810,996 | -13,236,900 | -26,958,247 | -17,384,520 | -25,409,301 | -33,776,450 |
| Earnings per share | - | - | - | - | - | - | - | - | - | - | -0.93 | -1.04 |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.93 | -1.04 |